VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Thursday morning. The brokerage issued a sell rating on the stock.

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Trading Up 1.6 %

VNRX opened at $0.70 on Thursday. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.23. The business’s fifty day simple moving average is $0.69 and its 200-day simple moving average is $0.68. The company has a market capitalization of $64.57 million, a price-to-earnings ratio of -1.94 and a beta of 1.10.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC raised its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.